News
Ipsen licenses Simcere ADC in $1bn-plus deal
Deal-hungry Ipsen is at it again, pledging around $1bn for rights to an antibody-drug conjugate (ADC) for cancer developed by China's Simcere.
News
AZ's ATR inhibitor ceralasertib flunks lung cancer test
AstraZeneca has had a setback in its oncology pipeline, as AKT inhibitor ceralasertib fails to improve survival in a phase 3 lung cancer trial.
R&D
Beyond good intentions: How life sciences can prove its read...
While support for reducing animal use has never been stronger, the path to broad adoption is steep and complex.
R&D
Q4 Clinical trials round-up: October to December 2025
We round up the key data and innovations in Q4 2025 - and what these likely presage for 2026’s R&D focus.
R&D
Big promises, hard work: What 2026 will demand from pharma
Eloise McLennan looks at a set of signals areas where pressure is building and 2026 looks set to demand more clarity, discipline, and follow-through.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
